F16.91
Hallucinogen use, unspecified, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
F16.91 refers to a history of hallucinogen use that is currently in remission, meaning the individual has ceased using these substances and is not experiencing active symptoms of use or dependence. Hallucinogens are substances that can distort perception, thought, and feeling, often leading to visual or auditory hallucinations. While some individuals may experience problematic use requiring treatment, others might have experimented with these drugs without developing a dependence. When such use is no longer ongoing and symptoms have subsided, healthcare providers classify this as 'in remission.' This classification helps in understanding a person's substance use history and planning appropriate ongoing care or support.
Causes & Symptoms
Clinical Causes: Previous use of hallucinogens such as LSD, psilocybin mushrooms, DMT, mescaline, or other related substances. Experimental exposure to hallucinogens driven by curiosity, peer influence, or psychological factors. Use of hallucinogenic substances as part of spiritual, religious, or cultural practices. Self-medication attempts for mental health issues using hallucinogens, which might have led to prior problematic use. Environmental and social factors that increase access and temptation to use hallucinogenic drugs.
Key Symptoms: Brief episodes of visual or auditory hallucinations during active use. Altered perception and sensory distortion while under the influence. Changes in mood, thoughts, and consciousness when intoxicated. Potential feelings of paranoia, anxiety, or confusion during intoxication. In some cases, flashbacks or persistent perception disorders even after stopping use. Absence of these symptoms when in remission, indicating cessation of use.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of hallucinogen use, unspecified, in remission is typically made based on patient history, self-reporting, and clinical assessment. Healthcare providers may review past substance use patterns and conduct interviews or questionnaires to determine if active use is present. Medical tests are generally not used to detect past use specifically but can rule out other causes of hallucinations or perception issues. The diagnosis emphasizes the history of use and current status of remission, helping in monitoring and planning future care.
Treatment Protocols: Managing a history of hallucinogen use involves supportive care, monitoring, and addressing any underlying mental health conditions. While active treatment may not be necessary if the individual remains in remission, ongoing support, counseling, and psychoeducation can be beneficial. If there is a concern about potential relapse or psychological effects, therapeutic interventions such as cognitive-behavioral therapy (CBT) or counseling may be recommended. It’s also important to maintain a healthy lifestyle and avoid environments or substances that could trigger a return to use.
Clinical Advice & FAQs
Billing Guidance
Is F16.91 a billable ICD-10 code?
Yes, F16.91 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.91?
Clinical documentation must specify the nature of Hallucinogen use, unspecified, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference
